Managing mCRPC in daily practice: a pragmatic approach

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 10 Jan 2014
Views: 3125
Dr Alison Birtle - Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK

Interesting personal case of Alison Birtle: a 69-year old man who developed mCRPC in 2008 and is still alive in September 2013. The patient had a good clinical response to docetaxel, cabazitaxel and abiraterone given sequentially but PSA was never informative.

“The physicians should be aware that such cases may happen and that treatment in such cases should be guided by clinical response and/or radiological response”.


Content taken from a Sanofi sponsored satellite symposium at ESMO 2013 as part of the official programme.